New evidence of a mitochondrial genetic background paradox: Impact of the J haplogroup on the A3243G mutation by Pierron, Denis et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
New evidence of a mitochondrial genetic background paradox: 
Impact of the J haplogroup on the A3243G mutation
Denis Pierron1,2,3, Christophe Rocher3, Patricia Amati-Bonneau4, 
Pascal Reynier4, Marie-Laure Martin-Négrier5, Stéphane Allouche6, 
Cécile Batandier7, Benedicte Mousson de Camaret8, Catherine Godinot9, 
Agnes Rotig10, Delphine Feldmann11, Christine Bellanne-Chantelot12, 
Benoit Arveiler13, Erwann Pennarun14, Rodrigue Rossignol3, Marc Crouzet2, 
Pascal Murail1, Didier Thoraval2 and Thierry Letellier*3
Address: 1Université Bordeaux 1, Laboratoire d'Anthropologie des Populations du Passé, UMR 5199 PACEA, 33400 Talence, France, 2Institut de 
Biochimie et Génétique Cellulaires, UMR 5095, CNRS, Université Victor Segalen-Bordeaux 2, 33076 Bordeaux, France, 3INSERM, U688 
Laboratoire de Physiopathologie Mitochondriale; Université Victor Segalen-Bordeaux 2, 33076 Bordeaux, France, 4INSERM, U694, Angers, F-
49033 France; Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, F-49033 France, 5Laboratoire d'Anatomie 
Pathologique, Centre Hospitalier Universitaire, Laboratoire d'Histologie-Embryologie, UFRII, Université Victor Segalen Bordeaux 2, 33076 
Bordeaux, France, 6Laboratoire de Biologie cellulaire et moléculaire de la signalisation, UPRES-EA 3919, Université de Caen, 14033 Caen, France, 
7Laboratoire de Biochimie et Génétique Moléculaire, Centre Hospitalier Universitaire de Grenoble, 38054 Grenoble, France, 8Laboratoire de 
Biochimie Pédiatrique, Hôpital Debrousse, 69322 Lyon, France, 9Centre de Génétique Moléculaire et Cellulaire, UMR 5534, CNRS, Université 
Claude Bernard de Lyon 1, 69622 Villeurbanne, France, 10Department of Genetics, INSERM U781 Hôpital Necker-Enfants Malades, 75743 Paris, 
France, 11Service de Biochimie et de Biologie Moléculaire, INSERM U587 Hôpital d'Enfants Armand-Trousseau, AP-HP, 75571 Paris, France, 
12Department of Cytogenetics, Hôpital Saint-Antoine-AP-HP, 75012 Paris, France, 13Pôle Génotypage-Séquençage, Université Victor Segalen 
Bordeaux 2, 33076 Bordeaux, France and 14Department of Evolutionary Biology, Institute of Molecular and Cell Biology, University of Tartu and 
Estonian Biocentre, Tartu, Estonia
Email: Denis Pierron - d.pierron@anthropologie.u-bordeaux1.fr; Christophe Rocher - crocher@u-bordeaux2.fr; Patricia Amati-
Bonneau - PaBonneau@chu-angers.fr; Pascal Reynier - PaReynier@chu-angers.fr; Marie-Laure Martin-Négrier - marie-laure.martin-
negrier@umr5541.u-bordeaux2.fr; Stéphane Allouche - allouche-s@chu-caen.fr; Cécile Batandier - Cecile.Batandier@ujf-grenoble.fr; 
Benedicte Mousson de Camaret - mousson@univ-lyon1.fr; Catherine Godinot - godinot1@yahoo.com; Agnes Rotig - roetig@necker.fr; 
Delphine Feldmann - delphine.feldmann@trs.ap-hop-paris.fr; Christine Bellanne-Chantelot - christine.bellanne@sat.ap-hop-paris.fr; 
Benoit Arveiler - Benoit.Arveiler@u-bordeaux2.fr; Erwann Pennarun - erwan@ebc.ee; Rodrigue Rossignol - rodrigue.rossignol@phys-mito.u-
bordeaux2.fr; Marc Crouzet - marc.crouzet@lbms.u-bordeaux2.fr; Pascal Murail - p.murail@anthropologie.u-bordeaux1.fr; 
Didier Thoraval - didier.thoraval@lbms.u-bordeaux2.fr; Thierry Letellier* - thierry.letellier@phys-mito.u-bordeaux2.fr
* Corresponding author    
Abstract
Background: The A3243G mutation in the tRNALeu gene (UUR), is one of the most common
pathogenic mitochondrial DNA (mtDNA) mutations in France, and is associated with highly
variable and heterogeneous disease phenotypes. To define the relationships between the A3243G
mutation and mtDNA backgrounds, we determined the haplogroup affiliation of 142 unrelated
French patients – diagnosed as carriers of the A3243G mutation – by control-region sequencing
and RFLP survey of their mtDNAs.
Results: The analysis revealed 111 different haplotypes encompassing all European haplogroups,
indicating that the 3243 site might be a mutational hot spot. However, contrary to previous
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findings, we observed a statistically significant underepresentation of the A3243G mutation on
haplogroup J in patients (p = 0.01, OR = 0.26, C.I. 95%: 0.08–0.83), suggesting that might be due to
a strong negative selection at the embryo or germ line stages.
Conclusion: Thus, our study supports the existence of mutational hotspot on mtDNA and a
"haplogroup J paradox," a haplogroup that may increase the expression of mtDNA pathogenic
mutations, but also be beneficial in certain environmental contexts.
Background
The mitochondrion is unique in that its bioenergetic and
biosynthetic systems are assembled from two different
information storage and retrieval systems: the nuclear-
cytosolic system, expressing nuclear DNA-encoded mito-
chondrial genes, and the mitochondrial system, express-
ing mitochondrial DNA-encoded genes. Maternally
inherited, mitochondrial DNA (mtDNA) encodes the 12S
and 16S mitochondrial rRNAs, 22 tRNAs, and 13
polypeptides, which form essential subunits of OXPHOS
enzyme complexes [1,2].
Over the past twenty years, genetic variations in mtDNA
have been linked to a number of multifactorial diseases
and aging [3], however, a large number of mutations were
considered neutral and used to define haplogroups in
order to investigate human origins [4], migrations, and
demographic events [5]. Indeed, human populations can
be divided into several mtDNA haplogroups on the basis
of specific nucleotid polymorphisms scattered throughout
the mitochondrial genome, reflecting mutation events
accumulated over time by a discrete maternal lineage.
Thus, for example, 95% of Europeans belong to 10 major
haplogroups [6] while 100% of Native Americans belong
to 5 major haplogroups [7,8].
Several recent studies have pointed out the possible
impact of haplogroups on mitochondrial physiology.
Indeed, Ruiz-Pesini et al. [9] revealed a possible impact of
haplogroups on the oxidative phosphorylation activity
that facilitates human adaptation to colder climates,
resulting in regional enrichment of specific mtDNA line-
ages (haplogroups). Moreover, haplogroups have been
shown to play a role in the phenotypic expression of dis-
eases [10]. Indeed, a link has been observed between hap-
logroups and various disorders and phenotypes; for
example, the haplogroup may influence the disease
expression of a mitochondrial pathogenic mutation, such
as T14484C and G11778A, found in Leber hereditary
optic neuropathy (LHON) [11-15].
The A3243G mutation [16-18] on the tRNALeu gene
(UUR) is one of the most common mitochondrial DNA
mutations worldwide and in France (unpublished data
from the French mitochondrial disease network). The
phenotypic expression of this mutation is quite variable,
ranging from mild to severe clinical phenotypes. Indeed,
while mtDNA the A3243G mutation is usually associated
with the MELAS syndrome (mitochondrial myopathy,
encephalopathy, lactic acidosis, and strokelike episodes:
MIM 540000) or MIDD (maternally inherited diabetes
and deafness: MIM 520000) [19]. This mutation is also
found in patients without any typical symptoms, but who
had clinical manifestations ranging from a mixture of
chronic progressive external ophthalmoplegia symptoms,
to strokelike episodes, cardiomyopathy, and progressive
kidney disease [20-23].
Several molecular mechanisms have been proposed to
explain the phenotypic expression of this mutation, such
as a reduced association of mRNA with ribosomes, possi-
bly due to the tRNALeu (UUR) aminoacylation defect
[24]. However, Kirino et al. recently proposed that a wob-
ble modification deficiency resulting in defective transla-
tion could be a key molecular factor responsible for the
phenotypic features of MELAS that would explain why the
different MELAS-associated mutations produce indistin-
guishable clinical features [25].
Several studies suggested that certain mtDNA haplo-
groups affected the phenotypic expression of this muta-
tion [26,27], but Torroni et al. and Deschauer et al.
recently concluded that European mtDNA backgrounds
did not have any substantial impact [28,29], however,
these studies involved only a small number of individuals
or poorly-defined populations. Thus it was impossible to
confirm the relationship between mutations responsible
for pathological conditions and haplogroups. Indeed, as
mentioned by Samuels et al. [30], large cohorts are
required to identify a reliable connection with complex
human diseases and geographical variations in haplo-
group frequencies.
In order to elucidate the relationships between mtDNA
the A3243G mutation and mitochondrial genetic back-
grounds, we used RFLP and sequencing to determine hap-
logroups of 142 patients diagnosed as carriers of the
A3243G mutation by the French mitochondrial disease
network.BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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Methods
A3243G patients
Screening for mitochondrial diseases was carried out by
the French mitochondrial disease network. This network
is made up of all the laboratories involved in genetic and
biochemical diagnosis of mitochondrial pathologies in
France. These laboratories collect samples from all French
patients suspected to be affected by mitochondrial dis-
eases, as the French health-care system makes it possible
for each individual to receive appropriate treatment. Over
the past fifteen years, 1,667 patients have been diagnosed
as carriers of a mitochondrial mutation. Patients showing
symptoms of MELAS, deafness, or mitochondrial diabetes
were tested for the A3243G mutation, using standard pro-
cedures. Among the cohort of individuals diagnosed as
carriers of the A3243G mutation over this period, we have
listed 142 unrelated patients tested by laboratories in Uni-
versity Hospitals of Angers, Bordeaux, Caen, Grenoble,
Lyon, and Paris. All these patients carried the A3243G
mutation and presented a mitochondrial pathology (Gen-
eral phenotype are presented in Table 1). Despite we have
detected qualitatively for all the A3243G patients the pres-
ence of heteroplamy (between 80 to 40%), the precise
percentage of heteroplasmy was not available for all the
patients. Genetic analyses were carried out with the appro-
priate consent of the patients.
Analysis of the haplogroups
Each patient's DNA was extracted from blood or muscle
using phenol/chloroform or Qiagene® QIAAmp DNA kit.
For each patient, the mitochondrial DNA control region
was amplified using the following primers: L15832 (light
chain, nps 15838–15858) and H408 (heavy chain nps
408–429). The amplification product were purified using
ExoSAP-IT®  technology. Finally, starting from position
16050, at least 725 pb of the mitochondrial DNA control
region were double-strand sequenced using an ABI Prism
BigDye Terminator Cycle Sequencing Ready Reaction Kit
(Perkin Elmer®). The same primers were used for amplifi-
cation and sequencing, L15832 and H408, together with
2 additional primers: L16200 (light chain, nps 16194–
16217) and H263 (heavy chain nps 263–285). Each indi-
vidual was also tested for the presence of a polymorphism
in position 7028 by digestion with the AluI restriction
enzyme after amplification with primers L6909 (light
chain, nps 6890–6909) and H7115 (heavy chain nps
7115–7131).
This made it possible to identify each individual's haplo-
type and haplogroup markers. The individuals' haplo-
group affiliation was determined on the basis of recent
studies involving total sequencing of mtDNA [31-34]
(Figure 1, Table 1). Affiliations to the main European hap-
logroups were confirmed by standard RFLP tests (UK:
12308HinfI; JT 4216NlaIII; J: 13704Bsto1; T: 15606AluI;
H7025AluI V 4577NlaIII; X:14465AccI; W: 8994HaeIII; I:
4529HaeII) on diagnostic positions for the haplogroups
on the mtDNA coding segment (Figure 1). We have used
the new haplogroup nomenclature recently proposed by
A. Torroni, A. Achilli, V. Macaulay, M. Richards, and HJ.
Bandelt [5] in order to classify the patients in haplo-
groups.
Control Population and Statistics
The patient's haplotype diversity was compared with a
French population sample (210 individuals) [35]. Indeed
this study was based on a similar methodology leading to
a similar haplotype resolution.
The distribution of carriers of the A3243G mutation
among the haplogroups was compared with frequencies
observed in a sample of the French population consisting
of 1,385 individuals [36]. Each haplogroup was tested as
a possible risk factor for developing the pathology, ini-
tially against the rest of the population, then versus hap-
logroup H. Statistical comparisons were carried out on
each haplogroup in turn, using standard "Khi 2" methods
without correction. The relative risk estimated for each
haplogroup was defined by the "odds ratio" method, with
a confidence interval calculated by the Miettinen method
[37].
Results
1 – Haplotypes and Phylogenetics (Figure 1)
mtDNA D-loop sequencing and RFLP analysis of the cod-
ing sequences revealed 111 different haplotypes, among
the 142 unrelated carriers of the A3243G mutation
(reported on Table 1 and in genbank-National Center for
Biotechnology Information with the accession numbers:
to EU519009 at EU519150). The ratio of haplotypes to
individuals was calculated as 0.78, similar to the value of
0.81 obtained in Dubut et al [35]. The most common hap-
lotype in our population, which is the most common in
french population sample, present in 13 individuals (hap-
lotype n°3), differed from the rCRS sequence by a single
transition in position 16519. We also found 11 pairs of
individuals with the same haplotype and 4 triplets. These
haplotypes are also regularly present in the French popu-
lation sample [35]. Thus the diversity of the population of
the A3243G mutation carriers was apparently, qualita-
tively and quantitatively similar to that of the French pop-
ulation as a whole.
We were also able to classify 139 patients out of 142 in
haplogroups with no ambiguity. For the 3 remaining indi-
viduals, a set of 4 RFLP tests (12308Hinf1; 4216NlaIII;
7025Alu I; 4577NlaIII) was carried out in order to pro-
ceed by elimination.BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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Table 1: RFLP and control-region mtDNA haplotypes from the French A3243G carriers. The patients were regrouped in three major 
phenotypes (Clear MELAS Syndrome, Partial MELAS syndrome and Diabetes Syndrome). 
Individ
u
haplotyp
e
haplogrou
p
RFLP POLYMORPHISM OBSERVED 
BETWEEN POSITION 16050–16569 
AND 1- 205
PHENOTYPE
11 H -7025AluI 16304, clear MELAS syndrome
21 H -7025AluI 16304, Partial MELAS syndrome
31 H -7025AluI 16304, clear MELAS syndrome
42 H -7025AluI 16354, Diabetes Syndrome
52 H -7025AluI 16354, Diabetes Syndrome
63 H -7025AluI 16519, Partial MELAS syndrome
73 H -7025AluI 16519, Diabetes Syndrome
83 H -7025AluI 16519, clear MELAS syndrome
93 H -7025AluI 16519, Diabetes Syndrome
10 3 H -7025AluI 16519, Diabetes Syndrome
11 3 H -7025AluI 16519, clear MELAS syndrome
12 3 H -7025AluI 16519, Partial MELAS syndrome
13 3 H -7025AluI 16519, clear MELAS syndrome
14 3 H -7025AluI 16519, clear MELAS syndrome
15 3 H -7025AluI 16519, Partial MELAS syndrome
16 3 H -7025AluI 16519, Diabetes Syndrome
17 3 H -7025AluI 16519, clear MELAS syndrome
18 3 H -7025AluI 16519, Diabetes Syndrome
19 4 H -7025AluI 16094,16278,16293,16311,195, clear MELAS syndrome
20 5 H -7025AluI 16114,16293,16311,16354,16519,195, clear MELAS syndrome
21 5 H -7025AluI 16114,16293,16311,16354,16519,195, Diabetes Syndrome
22 6 H -7025AluI 16126,16274,16519, Diabetes Syndrome
23 7 H -7025AluI 16126,16311,16519, Diabetes Syndrome
24 8 H -7025AluI 16126,16519,198, clear MELAS syndrome
25 9 H -7025AluI 16129,16316,16519, Partial MELAS syndrome
26 10 H -7025AluI 16129,16362,16482,16519, Partial MELAS syndrome
27 11 H -7025AluI 16129,16519, Diabetes Syndrome
28 12 H -7025AluI 16129,16519,10, Partial MELAS syndrome
29 13 H -7025AluI 16129,16519,10,189, clear MELAS syndrome
30 14 H -7025AluI 16129,16519,152, clear MELAS syndrome
31 15 H -7025AluI -12308HinfI; -4216NlaIII; 
+4577NlaIII
16162,16209,16519,73, Diabetes Syndrome
32 16 H -7025AluI 16166delA, Diabetes Syndrome
33 17 H -7025AluI 16169,16299,16519, Diabetes Syndrome
34 18 H -7025AluI 16183C,16189,16519, clear MELAS syndrome
35 19 H -7025AluI 16189,195, Partial MELAS syndrome
36 19 H -7025AluI 16189,195, clear MELAS syndrome
37 19 H -7025AluI 16189,195, clear MELAS syndrome
38 20 H -7025AluI 16213,16256,16519,9, Partial MELAS syndrome
39 21 H -7025AluI 16221,16519, Partial MELAS syndrome
40 22 H -7025AluI 16260,16357,16519, Diabetes Syndrome
41 22 H -7025AluI 16260,16357,16519, Partial MELAS syndrome
42 23 H -7025AluI 16261,16519, clear MELAS syndrome
43 24 H -7025AluI -12308HinfI; -4216NlaIII; 
+4577NlaIII
16278,16519,73, Partial MELAS syndrome
44 25 H -7025AluI 16290,16304,16519, Diabetes Syndrome
45 26 H -7025AluI 16290,16519,152, Diabetes Syndrome
46 27 H -7025AluI 16293,16519, Diabetes Syndrome
47 27 H -7025AluI 16293,16519, Diabetes Syndrome
48 28 H -7025AluI 16304,16325, clear MELAS syndrome
49 29 H -7025AluI 16311,16519, Diabetes Syndrome
50 29 H -7025AluI 16311,16519, Diabetes Syndrome
51 29 H -7025AluI 16311,16519, Diabetes Syndrome
52 30 H -7025AluI 16311,16519,93, Diabetes Syndrome
53 31 H -7025AluI 16362,16482, clear MELAS syndrome
54 32 H -7025AluI 16362,16482,16519,152, Partial MELAS syndrome
55 33 H -7025AluI 16519,143,152, Partial MELAS syndromeBMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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56 34 H -7025AluI 16519,151,152, Partial MELAS syndrome
57 34 H -7025AluI 16519,151,152, Partial MELAS syndrome
58 35 H -7025AluI 16519,152,199, Partial MELAS syndrome
59 35 H -7025AluI 16519,152,199, Partial MELAS syndrome
60 36 H -7025AluI 16519,56i,93, Diabetes Syndrome
61 37 H -7025AluI -12308HinfI; -4216NlaIII; 
+4577NlaIII
16519,73, clear MELAS syndrome
62 38 H -7025AluI 16519,93,95C, Partial MELAS syndrome
63 39 H -7025AluI 93,204, Partial MELAS syndrome
64 39 H -7025AluI 93,204, Diabetes Syndrome
65 40 H -7025AluI RCRS, Diabetes Syndrome
66 40 H -7025AluI RCRS, clear MELAS syndrome
67 41 R0* +7025AluI -12308HinfI; -4216NlaIII; 
+4577NlaIII
16311, Partial MELAS syndrome
68 42 R0* +7025AluI -12308HinfI; -4216NlaIII; 
+4577NlaIII
16311,16354, clear MELAS syndrome
69 43 R0a +7025AluI +4577NlaIII 16126,16362,16519,64, clear MELAS syndrome
70 44 V +7025AluI -4577NlaIII 16086,16298,72,73, Diabetes Syndrome
71 45 V +7025AluI -4577NlaIII 16129,16298,16311,72,195, Partial MELAS syndrome
72 46 V +7025AluI -4577NlaIII 16162,16298, clear MELAS syndrome
73 47 V +7025AluI -4577NlaIII 16278,16298,72, clear MELAS syndrome
74 48 V +7025AluI -4577NlaIII 16292,16298,72,195, Diabetes Syndrome
75 49 V +7025AluI -4577NlaIII 16298,16301,72, Partial MELAS syndrome
76 50 V +7025AluI -4577NlaIII 16298,16311,72, clear MELAS syndrome
77 51 V +7025AluI -4577NlaIII 16298,72, clear MELAS syndrome
78 52 V +7025AluI -4577NlaIII 16298,72,200, clear MELAS syndrome
79 53 V +7025AluI -4577NlaIII 16298,72,93, Diabetes Syndrome
80 54 HV0* +7025AluI +4577NlaIII 16129,16298,72,195, Diabetes Syndrome
81 55 HV0* +7025AluI +4577NlaIII 16298,72,195, Diabetes Syndrome
82 56 T1 +7025AluI +4216NlaIII; 
+13704BstOI
16126,16163,16186,16189,16294,16304,16519,
73,152,195,
clear MELAS syndrome
83 57 T1 +7025AluI +4216NlaIII; 
+13704BstOI
16126,16163,16186,16189,16294,16355,16356,
16519,73,
clear MELAS syndrome
84 58 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16147,16294,16296,16297,16304,16519,
73,
clear MELAS syndrome
85 59 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16153,16294,16390,16519,41,73,150, Diabetes Syndrome
86 60 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16172,16294,16296,16304,16519,73, Diabetes Syndrome
87 61 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16189,16292,16294,16519,73,146, Diabetes Syndrome
88 62 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16266,16294,16304,16519,73, clear MELAS syndrome
89 63 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16294,16296,16304,16454,16455,16519,
73,152,
Diabetes Syndrome
90 64 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16294,16296,16304,16519,73, Diabetes Syndrome
91 65 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16294,16296,16304,16519,73,146, Partial MELAS syndrome
92 66 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16294,16296,16519,73, Partial MELAS syndrome
93 67 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16294,16304,16519,73, clear MELAS syndrome
94 68 T +7025AluI +4216NlaIII; 
+13704BstOI
16126,16294,16519,73,146,152, Partial MELAS syndrome
95 69 J +7025AluI +4216NlaIII; -
13704BstOI
16069,16126,16234,16235,16519,73,185,188, Partial MELAS syndrome
96 69 J +7025AluI +4216NlaIII; -
13704BstOI
16069,16126,16234,16235,16519,73,185,188, Diabetes Syndrome
97 70 J +7025AluI +4216NlaIII; -
13704BstOI
16069,16126,16366,16390,16519,73,185,188, clear MELAS syndrome
98 71 U2 +7025AluI +12308HinfI 16051,16129,16189,16256,16519,73,152, Partial MELAS syndrome
99 72 U2 +7025AluI +12308HinfI 16051,16129C,16183C,16189,16319,16362,165
19,73,152,
Diabetes Syndrome
100 73 U2 +7025AluI +12308HinfI 16051,16129C,16183C,16189,16355,16362,165
19,73,152,
Diabetes Syndrome
Table 1: RFLP and control-region mtDNA haplotypes from the French A3243G carriers. The patients were regrouped in three major 
phenotypes (Clear MELAS Syndrome, Partial MELAS syndrome and Diabetes Syndrome).  (Continued)BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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For individuals 31, 43, and 61, the absence of digestion of
site RFLP 7025 indicated that they belonged to haplo-
group H, despite the absence of polymorphism A73G on
the D-loop, another characteristic of haplogroup H. The
analysis of the 4 RFLP of these 3 individuals clearly
excluded them from the other European haplogroups.
Individual 31 also had polymorphisms 16162 and 16209,
known to be associated with an A73G reversion [38].
These three individuals were, therefore, classified in hap-
logroup H.
The range of haplogroups was extremely wide and
included the typically European haplogroups H, R0a,
HV0, V, J, T, T1, K, U2, U5, U4, I, X, and W, as well as N1a
101 74 U2 +7025AluI +12308HinfI 16051,16183C,16189,16234,16266,16294,1651
9,16525,16558,73,152,199,
Diabetes Syndrome
102 75 U2 +7025AluI +12308HinfI 16051,16183C,16189,16234,16266,16294,1651
9,16525,73,152,199,
clear MELAS syndrome
103 76 K +7025AluI +12308HinfI 16093,16224,16260,16311,16519,44,73, Partial MELAS syndrome
104 77 K +7025AluI +12308HinfI 16093,16224,16311,16319,16519,73,195, Diabetes Syndrome
105 78 K +7025AluI +12308HinfI 16114A,16224,16311,16362,16519,73,195, Diabetes Syndrome
106 79 K +7025AluI +12308HinfI 16223,16224,16234,16311,16519,73,114, clear MELAS syndrome
107 80 K +7025AluI +12308HinfI 16224,16311,16519,64,73,146,152, Diabetes Syndrome
108 81 K +7025AluI +12308HinfI 16224,16311,16519,73, Diabetes Syndrome
109 82 K +7025AluI +12308HinfI 16224,16311,16519,73,146, clear MELAS syndrome
110 83 K +7025AluI +12308HinfI 16224,16311,16519,73,146,152, Diabetes Syndrome
111 84 K +7025AluI +12308HinfI 16224,16311,16519,73,146,185, Partial MELAS syndrome
112 85 K +7025AluI +12308HinfI 16224,16311,16519,73,146,195, clear MELAS syndrome
113 85 K +7025AluI +12308HinfI 16224,16311,16519,73,146,195, clear MELAS syndrome
114 86 U5 +7025AluI +12308HinfI 16148,16239,16270,73,150, Diabetes Syndrome
115 87 U5 +7025AluI +12308HinfI 16150,16172,16185,16189delT,16270,16274,16
311,16465,16519,73,150,152,
Partial MELAS syndrome
116 88 U5 +7025AluI +12308HinfI 16168,16192,16256,16270,16526,73, Partial MELAS syndrome
117 89 U5 +7025AluI +12308HinfI 16189,16192,16270,16398,73,150, Diabetes Syndrome
118 90 U5 +7025AluI +12308HinfI 16192,16256,16270,16278,16294,16391,16526,
64,73,
Diabetes Syndrome
119 91 U5 +7025AluI +12308HinfI 16192,16270,16319,16526,73,150, Partial MELAS syndrome
120 92 U5 +7025AluI +12308HinfI 16192,16270,16319,73,150, Diabetes Syndrome
121 93 U5 +7025AluI +12308HinfI 16256,16270,16399,73, clear MELAS syndrome
122 94 U5 +7025AluI +12308HinfI 16270,16296,58,59G,64,73,150,200, clear MELAS syndrome
123 95 U4 +7025AluI +12308HinfI 16219,16356,16519,73,195, clear MELAS syndrome
124 95 U4 +7025AluI +12308HinfI 16219,16356,16519,73,195, Diabetes Syndrome
125 95 U4 +7025AluI +12308HinfI 16219,16356,16519,73,195, Diabetes Syndrome
126 96 U4 +7025AluI +12308HinfI 16295,16356,16519,73,195, Diabetes Syndrome
127 97 U4 +7025AluI +12308HinfI 16356,16519,73,146,195, clear MELAS syndrome
128 98 U4 +7025AluI +12308HinfI 16356,16519,73,195, clear MELAS syndrome
129 99 U5 +7025AluI +12308HinfI 16189,16192,16270,16311,16336,55,73,150, clear MELAS syndrome
130 100 X +7025AluI +14465AccI 16129,16189,16223,16278,16290,16362,16519,
73,153,195,
clear MELAS syndrome
131 101 X +7025AluI +14465AccI 16186,16189,16223,16278,16297,16519,73,153,
195,
Diabetes Syndrome
132 102 X +7025AluI 16186,16189,16223,16278,16519,73,153,188,19
5,
Partial MELAS syndrome
133 103 I +7025AluI -4529HaeII 16129,16223,16304,16391,16519,73,199,204, Diabetes Syndrome
134 103 I +7025AluI -4529HaeII 16129,16223,16304,16391,16519,73,199,204, Partial MELAS syndrome
135 104 N1b +7025AluI 16145,16176G,16223,16390,16519,73,151,152, clear MELAS syndrome
136 105 N1a +7025AluI 16147A,16172,16223,16248,16355,16519,73,19
9,204,
clear MELAS syndrome
137 106 L2 +7025AluI 16129,16189,16192,16223,16274,16278,16294,
16309,16390,73,143,146,152,195,
Diabetes Syndrome
138 107 L2 +7025AluI 16183C,16189,16223,16266,16274,16278,1639
0,16519,73,152,195,
Partial MELAS syndrome
139 108 D +7025AluI -12308HinfI 16221,16223,16291,16362,16390,16519,73, clear MELAS syndrome
140 109 W +7025AluI -8994HaeIII 16223,16280,16292,16519,73,119,189,195,204, clear MELAS syndrome
141 110 D +7025AluI 16223,16295,16362,16519,73,146,199, Diabetes Syndrome
142 111 I +7025AluI -4529HaeII 16223,16311,16391,16519,73,199,204, clear MELAS syndrome
Partial MELAS syndrome patients are patients who present some, but not all of the typical MELAS symptoms. - Detailed haplogroups [5] and haplotypes
Table 1: RFLP and control-region mtDNA haplotypes from the French A3243G carriers. The patients were regrouped in three major 
phenotypes (Clear MELAS Syndrome, Partial MELAS syndrome and Diabetes Syndrome).  (Continued)BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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and N1b, plus two representatives each of African haplo-
group L2, and Asian haplogroup D (figure 1). The pres-
ence of the last two haplogroups is not unexpected, since
African mtDNAs are not uncommon in France and mem-
bers of Asian super-haplogroup M are sporadically identi-
fied in Europe [36].
2 – Haplogoup frequencies observed among A3243G 
patients
The Figure 1 represents the patients distribution on a phy-
logenetic tree of the European population based on recent
total sequencing studies of mitochondrial DNA [33]. The
wide distribution of our patients on this tree confirmed
our haplotype observations, i.e.: the existence of a great
number of mutation events A3243G.
In light of these results (Table 1, Figure 1), we investigated
whether there was a difference in distribution among hap-
logroups of the patient population carrying the A3243G
mutation compared to the reference population. We
therefore compared the distribution of the 142 A3243G
mutation carriers among European haplogroups with the
frequencies obtained for 1,385 unrelated French people
[36].
For the purposes of statistical comparison, we collected
individuals in phylogenetic clusters centered on super-
haplogroup R. This point was chosen as it corresponded
to the node where the R line, which represents 90 % of the
French population, divides off from the rest of the human
phylogeny. We then analyzed whether each cluster consti-
tuted a risk factor compared to the rest of the population.
We tested the 4 largest clusters representative of a phylo-
genic reality, as well as the haplogroups or smaller sub-
haplogroups, so that we could use Khi2 without correc-
tion (Table 2).
Super-haplogroup R0 (formerly PreHV*)
Haplogroup R0 included 81 patients (Figure 1), i.e. 57.0%
of the A3243G mutation carriers. The slight overrepresen-
tation (OR: 1.21, C.I. 95%: 0.85–1.71) of this haplogroup
was not significant (p = 0.29) (Table 1). To obtain more
detailed results, we applied the same tests to all suffi-
ciently large sub-clusters of R0, i.e. haplogroups H and
Phylogenical repartition of the 111 different haplotypes observed in the 142 A3243G carriers Figure 1
Phylogenical repartition of the 111 different haplotypes observed in the 142 A3243G carriers. The phylogenic 
tree was based on recent total sequencing studies of mitochondrial DNA [33]; the new haplogroup nomenclature is used [5]. 
The different polymorphisms used for haplogroup determination in this study are indicated in blue. The red crosses indicate 
the number of individuals per haplogroup.BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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HV0. This revealed an overrepresentation of haplogroup
HV0 (formerly pre-V) (OR: 1.83, C.I. 95%: 0.96–3.47),
however this result is not clearly significant (p = 0.06).
Individuals in haplogroup HV0 had 12 distinct haplo-
types, which would seem to exclude the possibility that
overexpression of this haplogroup was due to a single
mutation event. The frequency of haplogroup H did not
seem significantly different from that observed in the con-
trol population (p = 0.73). In view of the lack of data on
the proportions of H sub-haplogroups in the French pop-
ulation, as well as the considerable variation in the fre-
quency of sub-haplogroups in Western Europe [32], we
decided not to subdivide this haplogroup.
Super-haplogroup UK
22.5% of our patients were identified as belonging to hap-
logroup UK, which was not significantly different from
the French population (p = 0.86, OR: 1.04, C.I. 95%:
0.69–1.57). As in the case of haplogroup R0, we tested for
significant differences in the sub-clusters of this haplo-
group, however, there was no significant difference for
sub-clusters U5 (p = 0.60), U1811 (p = 0.51), or K (p =
0.70).
Super-haplogroup OTHER
All the patients who were not in super-cluster R were clas-
sified in super-haplogroup OTHER. This was, therefore, a
broadly paraphyletic group, including haplogroups: N1, I,
W, X, M, and L. 13 patients were classified in this haplo-
group. The comparison of this cluster with the "OTHER"
group of the reference study has detected no significant
difference (p = 0.89, OR = 0.96, C.I. 95%: 0.53–1.75)
Super- haplogroup JT
Haplogroup JT represented 11.3% of our study popula-
tion, and was, therefore, slightly underrepresented (p =
0.12, OR = 0.66, C.I. 95%: 0.38–1.13). J haplogroup, with
only 3 individuals, seemed very significantly underrepre-
sented among our patients (p = 0.01, OR = 0.26, C.I. 95%:
0.08–0.83). Moreover, these 3 patients can be caracterised
by a later onset (between 20–40 years) but with no spe-
cific symptomatology, toward the MELAS patients. There
was not, apparently, any significant difference in haplo-
group T (p = 0.79, OR = 1.08, C.I. 95%: 0.59–1.98). The
underrepresentation of Haplogroup JT was apparently,
simply due to underrepresentation of J.
Using haplogroup H as a reference
We also tested whether each cluster constituted a risk fac-
tor in comparison to a single reference haplogroup. As
presented by van der Walt et al. [39] using a reference hap-
logroup is more homogeneous than the sum of the vari-
ous haplogroups. In addition, it was possible to compare
each haplogroup variation between the control popula-
tion and our patients with the variation in the same refer-
ence haplogroup. The choice of haplogroup H as a
reference was based on the fact that it did not seem to vary
significantly between the control and patient populations.
In addition, the haplogroup H was the most widely repre-
sented in the French population. The results of this analy-
sis (Table 3) confirmed the absence of variation for
clusters OTHER, UK, and T (p > 0.6) and emphasized the
underexpression of J (p = 0.02, OR = 0.27, C.I. 95%: 0.08–
0.87). Moreover, the overexpression of HV0 is no more
observed (p = 0.10, OR = 1.73, C.I. 95%: 0.89–3.36).
Discussion
The A3243G mutation, located on the tRNALeu gene
(UUR) [16], is one of the most common mitochondrial
DNA mutations worlwide. The phenotypes associated
with this disease are highly variable and heterogeneous.
The impact of mitochondrial genetic background is
increasingly being considered, in explanation of the phe-
notype variability common to pathogenic mitochondrial
mutations. Each phenotype would, therefore, consist of
one main pathogenic mutation, associated with second-
ary mutations, which modulate the expression of the
main mutation. Secondary mutations do not necessarily
Table 2: Relative risk estimated (Odds ratio: O.R.) of each haplogroup to develop the pathology against the rest of the population. 
Haplogroup 3243 carriers French Population O.R. P. value C.I. at 95%
R0 57.0% 52.4% 1.21 0.29 0.85–1.71
> H 46.5% 45.6% 1.04 0.84 0.73–1.46
> HV0 8.5% 4.8% 1.83 0.06 0.96–3.47
JT 11.3% 16.2% 0.66 0.12 0.38–1.13
> T 9.2% 8.5% 1.08 0.79 0.59–1.98
> J 2.1% 7.7% 0.26 0.01 0.08–0.83
UK 22.5% 21.9% 1.04 0.86 0.69–1.57
> U5 7.0% 8.3% 0.84 0.60 0.43–1.64
> U1811 15.5% 13.5% 1.17 0.51 0.73–1.90
>> K 7.7% 8.7% 0.88 0.70 0.46–1.68
OTHER 9.2% 9.5% 0.96 0.89 0.53–1.75
The new haplogroup nomenclature is used (Torroni et al. 2006). C.I.: Confidence Interval.BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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have any impact on the phenotype of an individual who
does not carry the main mutation and are, therefore, gen-
erally considered to be polymorphisms.
Progress in mitochondrial phylogeny has made it possible
to classify mitochondrial genotypes (haplotypes) in
monophyletic lines (haplogroups). Thus, two mitochon-
drial haplotypes in the same haplogroup will have the
same phylogenetic background and, therefore, share a cer-
tain number of polymorphisms [5].
To determine whether these polymorphisms have an
impact on pathogenic mitochondrial mutations, previous
studies investigated the statistical correlations between
pathogenic mutations and mitochondrial haplogroups
[10]. Most of these studies have been carried out with very
small cohorts. The largest cohort of bearers of the same
mutation from a single population to date consisted of 67
Italian patients with mutation 11778 [12]. Previous Euro-
pean research into the A3243G mutation analyzed data
from 35 Spains [29], 11 Finns [40], and 7 Dutch [15]. As
suggested by Samuels et al [30]; in order to make inform-
ative statistical analysis, this type of study requires a max-
imum number of patient carrying the same pathogenic
mutation within the same population. To overcome this
difficulty, the present study included almost all the
patients diagnosed by the French mitochondrial pathol-
ogy network in recent years. Besides including a large
number of unrelated patients (142), this made it possible
to study a population of patient spread all over the French
territory. Furthermore, the French health care system pro-
vides access to treatment to all individuals living in
France, so our results are not biased by the possible
recruitment of specific sub-classes of the population.
Appearance of the A3243G mutation
The present study showed that the A3243G mutation car-
riers were distributed among all the haplogroups com-
monly found in the European population. This may
suggested that the A3243G mutation appeared many
times, as hypothesized in previous studies [15,29,40].
Moreover, the genetic diversity of our population is quan-
titatively and qualitatively similar to that of the French
population. The population of patients carrying the muta-
tion A3423G did not, therefore, seem to have been
affected by founding events, but, on the contrary, to be
due to a large number of independent mutation events.
In a similar analysis of LHON pathology, it was suggested
that the number of independent mutation events could be
assimilated to the number of different haplotypes [12].
Indeed, the haplotypes found in the patient population
were found at random in a sample of the reference popu-
lation. Similarly, the haplotypes found in our patient pop-
ulation were also present in our reference sample. The
presence of these haplotypes in the reference population
indicated that most of the 3243 mutation events had
appeared independently in haplotypes existing in the
healthy population.
Furthermore, the most common haplotype in our popula-
tion (n°3) was associated with separate H sub-haplo-
groups [38], which are also very common in the French
population. Therefore, it is highly probable that the
patients who had this same haplotype resulted from sev-
eral independent mutation events. Following analysis of
111 haplotypes, we therefore suggest that at least 111
A3243G transition events have occurred recently in the
French population.
Antonio Torroni et al [29] suggested classifying the
A3243G mutation as a "severely deleterious" mutation,
according to the Douglas Wallace classification [41]. This
category includes heteroplasmic mutations that produce a
very handicapping phenotype, transmitted only over very
few generations. Our results confirmed this classification
of the A3243G mutation. In this "severely deleterious"
mutation scenario, individuals affected by the A3243G
Table 3: Relative risk estimated (Odds ratio: O.R.) of each haplogroup to develop the pathology against the H haplogroup. 
Haplogoup 3243 carriers French Population O.R P. value C.I. at 95%
R0 57.0% 52.4%
> H 46.5% 45.6%
> HV0 8.5% 4.8% 1.73 0.10 0.89–3.36
JT 11.3% 16.2% 0.68 0.18 0.39–1.20
> T 9.2% 8.5% 1.06 0.86 0.56–1.98
> J 2.1% 7.7% 0.27 0.02 0.08–0.87
UK 22.5% 21.9% 1.01 0.97 0.65–1.57
> U5 7.0% 8.3% 0.83 0.60 0.42–1.67
> U1811 15.5% 13.5% 1.13 0.65 0.68–1.87
>> K 7.7% 8.7% 0.87 0.69 0.45–1.70
OTHER 9.2% 9.5% 0.95 0.86 0.51–1.76
The new haplogroup nomenclature is used (Torroni et al. 2006). C.I.: Confidence Interval.BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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mutation on 16.3/100,000 [42] would seem to result
mainly from recurrent mutation phenomena, rather than
founding effects associated with mutation transmission
and propagation phenomena.
This large number of independent mutation events is
apparently linked to the existence of a mutation hot spot
on tRNA leucine 1 [43,44]. Indeed, 24 "probable" patho-
genic mutations, including 7 "confirmed", have been
identified on the Mitomap Website for tRNA leucine 1
(where the A3243G mutation is located), which is 70 base
pairs long. This level of mutation seems particularly high
compared with tRNA leucine 2, where only 5 "probable"
pathogenic mutations have been identified, including
only 1 "confirmed". tRNAleu 1 and tRNAleu 2 have
approximately the same length and the same function, so
the higher mutation rate of tRNAleu 1 may be due to its
second function. Indeed the sequence of tRNAleu 1 is
implied with the mTERF factor in a mitochondrial DNA
transcription termination zone; furthermore, this tran-
scription mechanism has been shown to involve the for-
mation of two loops [45]. It is, therefore, possible that this
mechanism blocking mitochondrial RNA-polymerase
(mtRPOL) activity is also able to reduce the accuracy of
DNA-polymerase γ.
Taken together, our findings demonstrated the absence of
a decrease in diversity within the patient haplogroups.
This indicated that mitochondrial genetic background
had no impact on mutation events and did not, therefore,
affect the mutation rate of position A3243G.
Impact of mitochondrial genetic background
Although genetic background does not affect the fre-
quency of mutation 3243, it may modulate its expression.
We compared the distribution of 142 unrelated French
patients affected by the A3243G mutation among Euro-
pean haplogroups, with that of the French population
sample of 1,385 individuals described by Richard et al.
The distribution of the A3243G mutation carriers among
European haplogroups revealed a significant difference in
J haplogroup compared to the French population. These
differences apparently demonstrated a link between hap-
logroups and the A3243G mutation and, therefore, that
mitochondrial genetic background had an impact on the
A3243G mutation. These findings are apparently in con-
tradiction with a previous study involving 35 Spanish
patients [29], however, the lack of differences in the Span-
ish cohort may probably due to the small size of the sam-
ples.
The impact of genetic background on mutation T14484C,
which is related to LHON pathology, was more striking, as
75% of the carriers of this mutation belonged to J haplo-
group. However, the significant presence of the A3243G
mutation in all European haplogroups may be explained
by a combination of 3 factors: (i) a high mutation rate;
(ii), the absence of polymorphisms related to European
haplogroups located directly on tRNAleu 1, which makes
it impossible to compensate or aggravate directly this
mutation; (iii) tRNA function itself, necessary for the tra-
duction of all the mitochondrial genes, which makes it
impossible to have a global compensation by the presence
of a polymorphism located on a single gene.
J haplogroup was markedly underrepresented among the
A3243G mutation carriers. There are different possibilities
to explain this observation. It might be possible that (i)
this combination produced a phenotype not commonly
considered to be from mitochondrial origin. Then, these
patients would not be studied for mtDNA mutations and
they would form part of other patient populations.
J haplogroup could also (ii) be a protective genetic back-
ground. However, this hypothesis is relatively improbable
for several reasons. First, tRNA leucine is not affected by
any polymorphisms linked with J haplogroup, so it is dif-
ficult to hypothesize compensation in terms of tRNA leu-
cine conformation. Second, as explained in the previous
paragraph, is highly improbable that the related polymor-
phisms of J are able to produce a global compensation of
the A3243G mutation. Finally, if the A3243G mutation
were attenuated in J haplogroup, due to its high mutation
rate, it could be identified in the sample of healthy fully-
sequenced individuals belonging to J haplogroup (Mito-
map). However, if we did not find it, the hundred of
mtDNA J published sequences that we have now are not
enough to find this combination on the general popula-
tion. For example, if the A3243G frequency was 16 out of
100,000 individuals (1 out of 6,250) and the population
frequency of the haplogroup J is around 10%, 62,500
individuals should be sequenced to find the mutation in
the general population.
In light of these facts, we put forward a third hypothesis,
(iii): the association of J haplogroup and A3243G is life-
threatening, and therefore lethal to the embryo or germ
line. This hypothesis agrees more closely with previous
findings that associate J with a number of diseases, such as
LHON [11-13], diabetes [46], and optic neuritis [47] (Fig-
ure 2). The life-threatening action of J haplogroup has
been suggested to have resulted from an accumulation of
non-synonymous polymorphisms on the cytochrome b
gene [12]. These complex III damages affects, more specif-
ically, the CoQ binding sites, thus upsetting the proton
pump Q cycle and, finally, Oxidative Phosphorylation
(OXPHOS) coupling (Figure 2) [2,9]. Some authors sug-
gested that this OXPHOS uncoupling characteristic was an
ancient mitochondrial adaptation to the cold, as it pro-
moted heat production [8]. The same authors suggestedBMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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that this uncoupling would reduce ROS production, lead-
ing to a lower gradual mitochondria degradation
observed in aging. This could explain the overrepresenta-
tion of J among populations of people over 100 years
[48,49].
Taken together, these points emphasize the paradox of
haplogroup J, which may promote the expression of mito-
chondrial mutations in certain individuals, but also be
beneficial for others. Figure 2 summarizes what we named
"J paradox", showing the impact of polymorphisms in J
haplogroup on the OXPHOS level, their implications on
an individual level, and their impact on the distribution
of populations studied within the phylogeny. This para-
dox, already described by D.C. Wallace, E. Ruiz-Pesini,
and A. Torroni (importance of cytochrome b, relationship
between long lifespan, adaptation, and predisposition for
diseases), clearly indicates that the distribution of J haplo-
group in a patient population could vary considerably
and, above all, that this distribution could provide infor-
mation on the type of mutation and the mechanism
involved.
Thus, the effect of a slight decrease of the mitochondrial
activity (from a genetic or environmental origin) would
be amplified by polymorphisms related to J, resulting in a
high proportion of J haplogroup in the patient popula-
tion. In the case of a more deleterious mutation (as pre-
sented here), amplification of the pathology resulted in a
lower viability of J-3243 patients, and therefore a low pro-
portion of J among patients with this severe pathology.
Conclusion
Taken together, these findings show that the A3243G
mutation has appeared independently on many occasions
in the French population, thus confirming the presence of
a mutation hot spot on tRNA leucine 1. Inter-haplogroup
differences in mitochondrial genetic backgrounds appar-
ently had no impact on the mutation rate of position
3243. However, there is a link between the haplogroup,
especially J haplogroup, and expression of the mutation.
Our study confirmed the susceptibility of this haplogroup
to the expression of pathologies of mitochondrial origin.
If the Western Eurasian haplogroup J appears to be associ-
ated to the prevalence of the A3243G mutation, it is
highly provable that other haplogroups from other
regions of the world could be associated. In this sense, two
different studies found, first, a higher frequency of the 9
bp deletion in Taiwan MELAS patients [26] and, second,
an overrepresentation of the T16189C polymorphism in
Hypothetical mechanism of the "J paradox" Figure 2
Hypothetical mechanism of the "J paradox". The impact of J polymorphisms can differed toward the mitochondrial envi-
ronment. This figure summarizes these impacts on the OXPHOS level, their implications on an individual level, and their 
impact on the distribution of populations studied within the phylogeny.BMC Medical Genetics 2008, 9:41 http://www.biomedcentral.com/1471-2350/9/41
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patients with the A3243G mutation [50] Both markers
define mtDNA haplogroup B.
These results highlight the importance of analyzing mito-
chondrial genetic background when studying mitochon-
drial diseases. Indeed, patients' haplogroups could be a
part of the diagnostic procedure for mitochondrial dis-
eases, in order to obtain a clearer understanding of their
modulation mechanisms, and therefore adjust the diag-
nosis.
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